Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is a Healthcare company (Biotechnology) with a market capitalization of $1.7B. The Maz Rating grades it against the other companies in its sector.
Recursion Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.72, Recursion Pharmaceuticals, Inc. trades at 24.6x sales and 1.6x book value. Over the last twelve months it generated about $69M of revenue and a net loss of $567M. It runs a gross margin of 10.7%, an operating margin of -725.4% and a net margin of -697.1%. It shows return on equity of -47.8%, return on invested capital of -43.7% and a free cash flow yield of -18.6%. On the balance sheet: a debt-to-equity ratio of 0.08 and a current ratio of 5.01. Over the past 52 weeks the share price ranged from $2.50 to $5.24, with a beta of 1.03.
Recursion Pharmaceuticals, Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 4 Buy and 6 Hold, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Recursion Pharmaceuticals, Inc. (RXRX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.61% / 30% · (Cash+Inv) / Mkt Cap (36m) 28.1% / 30% · Interest income / Revenue 26.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.61% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 28.1% / 33% · Receivables / Mkt Cap (36m) 1.74% / 49% · Interest income / Revenue 26.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.61% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 28.1% / 33.33% · Receivables / Mkt Cap (24m) 1.74% / 33.33% · Interest income / Revenue 26.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.90% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 47.5% / 33.33% · Receivables / Avg Assets (4Q) 1.65% / 33.33% · Interest income / Revenue 26.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.97% / 33.33% · (Cash+ST Inv) / Total Assets 45.0% / 33.33% · (Cash+Recv) / Total Assets 47.8% / 33.33% · Interest income / Revenue 26.0% / 5% | Fail |
No. As of September 2026, Recursion Pharmaceuticals, Inc. (RXRX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Recursion Pharmaceuticals, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 26.0% of each dividend: Recursion Pharmaceuticals, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.